← Leaderboards
Eileen Carry
Zena Therapeutics Inc.
$368,300
Attributed
$368,300
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $313.3K · FY2023–24$500K$375K$250K$125K$0
'23
'24
Funding mix
By agency
NIH$368,300 · 1
By mechanism
R41$368,300 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Prevent”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Melissa Basford · Vanderbilt University Medical Center$37,410,924
- David Annett · Information Management Services, Inc.$34,721,865
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Lee Lichtenstein · Vanderbilt University Medical Center$26,108,724
- Dorota A. Grejner-Brzezinska · University Of Wisconsin-Madison$19,883,568
Research focus
PreventStandard Of CareMarketingPanic DisorderProgramsReceptorInnovation CorpsLinkOpioid OverdoseOverdose DeathProbabilityAnxiety DisordersCommercializationComparative EfficacyEpidemicInnovationBenzodiazepinesIn VivoAnxietyOpioidOpioid Use DisorderEnrollmentCentral Nervous System DepressantsUnited States National Institutes Of Health
Grant awards (2)
Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.$55,000
R41 · FY2024 · DA · contact PI
Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.$313,300
R41 · FY2023 · DA · contact PI